Mobile app support for young women with breast cancer
Official title: Utility of a Mobile Application for Young Women With Breast Cancer
Run by Wake Forest University Health Sciences · NCT07009093 · Data updated 2026-11-12
This project will test whether the Mighty Pro mobile app can help lower cancer-related distress in women aged 18–45 with breast cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Status | Recruiting |
| Started | September 2026 |
| Main results expected | July 2027 |
| Study ends | January 2030 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT07009093 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking female patients aged 18–45 with histologically confirmed breast cancer, an NCCN Distress Thermometer score of 4 or higher, access to a mobile device and email, and who are established patients at the enrolling center.
✕Probably not a fit
Patients older than 45, those with low baseline distress, those without a smartphone or email, non-English speakers, or those who prefer in-person support may not receive benefit from this mobile-app intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized, two-stage intervention conducted through Wake Forest/Atrium Health cancer centers enrolling women 18–45 with breast cancer who report significant distress (NCCN Distress Thermometer ≥4). Participants will use the Mighty Pro mobile application, which offers social connectivity and educational content, and outcomes will be compared between randomized groups. The study measures feasibility of implementing the app and its effect on patient-reported cancer-related distress using validated distress screening. Enrollment is limited to English-speaking patients with access to a mobile device and an active email address.
Why it matters
Potential benefit: If successful, the app could reduce cancer-related distress and improve social support and access to information for young women with breast cancer.
How similar studies have gone: Related mobile and online psychosocial interventions for cancer patients have shown mixed but generally promising results in reducing distress, though few prior trials focus specifically on young women with breast cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 18 and ≤ 45 years at the time of consent * Female * Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC) * Histological confirmation of any type and stage (0-IV) of breast cancer * Screening (baseline) NCCN Distress Thermometer score ≥ 4 * Access to a mobile device for trial purposes and an active email address * Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only. * As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study Exclusion Criteria: \- None
Where it's running
-
Atrium Health Levine Cancer
Charlotte, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Julie Fisher, MD — Wake Forest University Health Sciences
- Study coordinator: Maggie Dzhanumova
- Email: margarita.dzhanumova@advocatehealth.org
- Phone: 704-754-3768
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.